Candel Therapeutics Inc’s recently made public that its Officer WILLIAM GARRETT NICHOLS acquired Company’s shares for reported $17606.0 on Jun 30 ’25. In the deal valued at $4.90 per share,3,593 shares were bought.
Then, Nichols William Garrett sold 45,316 shares, generating $396,995 in total proceeds. Upon selling the shares at $8.76, the Chief Medical Officer now owns 52,493 shares.
Before that, Barone Francesca sold 32,146 shares. Candel Therapeutics Inc shares valued at $281,673 were divested by the Chief Scientific Officer at a price of $8.76 per share. As a result of the transaction, Barone Francesca now holds 96,527 shares, worth roughly $0.49 million.
A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. Canaccord Genuity began covering CADL with “Buy” recommendation on February 19, 2025. BofA Securities started covering the stock on February 07, 2025. It rated CADL as “a Buy”.
Price Performance Review of CADL
On Monday, Candel Therapeutics Inc [NASDAQ:CADL] saw its stock jump 3.27% to $5.06. Over the last five days, the stock has gained 8.35%. Candel Therapeutics Inc shares have fallen nearly -11.38% since the year began. Nevertheless, the stocks have fallen -41.71% over the past one year. While a 52-week high of $14.60 was reached on 02/20/25, a 52-week low of $3.79 was recorded on 04/09/25.
Levels Of Support And Resistance For CADL Stock
The 24-hour chart illustrates a support level at 4.88, which if violated will result in even more drops to 4.70. On the upside, there is a resistance level at 5.24. A further resistance level may holdings at 5.42.
How much short interest is there in Candel Therapeutics Inc?
A steep rise in short interest was recorded in Candel Therapeutics Inc stocks on 2025-06-13, growing by 41584.0 shares to a total of 6.26 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.22 million shares. There was a rise of 0.66%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 02, 2022 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $11 price target.
